The global digital pathology market size was valued at USD 1,022.14 Million in 2024 and is projected to reach USD 2,320.06 Million by 2033, exhibiting a CAGR of 8.54% during 2025-2033. North America dominates with over 40.7% market share in 2024. Key growth drivers include the rising demand for advanced diagnostic tools, increasing chronic disease prevalence, technological advances in AI, healthcare digitization, and supportive regulatory frameworks. The study provides a detailed analysis of the industry, including the digital pathology market size, trends, growth, size, and industry growth forecast.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Digital Pathology Market Key Takeaways

• Current Market Size: USD 1,022.14 Million in 2024
• CAGR: 8.54% during 2025-2033
• Forecast Period: 2025-2033
• North America accounted for over 40.7% market share in 2024, driven by high-tech healthcare infrastructure and significant investments in healthcare IT.
• The human pathology segment leads with about 62.2% market share in 2024, due to its critical role in disease diagnosis.
• Scanners dominate the product segment, essential for digitizing histopathological slides.
• The academic and research institutes end-user segment holds around 45.7% market share due to its use in education and research.
• The on-premises delivery model is preferred for data security and control by large institutions.

Request for a Free Sample Report:  https://www.imarcgroup.com/digital-pathology-market/requestsample

Market Growth Factors

The market is driven by the increasing demand for advanced diagnostic technologies and the increasing prevalence of chronic diseases including cancer. It is estimated that by 2024, there will be more than 2 million new cases of cancer and more than 600 thousand cancer deaths. This has led to the development of new AI, machine learning, and workflow automation technologies aimed at improving cancer diagnostics in these regions. For instance, Roche's systems have over 20 machine learning algorithms integrated into their systems, indicating a strong interest in improving cancer diagnostics.

Advances in imaging technology and software, artificial intelligence and machine learning which improve the quality of images and automated analysis and diagnosis, and predictive diagnostics have also driven market growth. Health outcomes are expected to improve by 40% and treatment costs to reduce by 50%. Integration with electronic medical record systems and lab information systems, as well as practice of collaborative medicine, is expected to drive the growth of the market globally.

Telepathology or sharing of high quality slides from a distance is expected to drive the market further as it uses high quality images to stretch limited resources further, particularly for the remote areas. It is expected to help address the shortage of 10 million health care workers worldwide, expected by 2030 (World Health Organization (WHO) estimates). It also enables scalability through cloud-based data storage and serves as an essential element within the global healthcare network.

Market Segmentation

By Product:

• Scanners: Lead the market as they digitize histopathological slides, offering high-resolution images for analysis, storage, and sharing, crucial for handling increased pathology sample volumes.
• Software: Not separately described in detail in source.
• Storage Systems: Not separately described in detail in source.
• Communication Systems: Not separately described in detail in source.

By Type:

• Human Pathology: Holds around 62.2% market share in 2024, playing a pivotal role in diagnosing human diseases, with enhanced accuracy due to digital archiving and AI integration.
• Veterinary Pathology: Not separately described in detail in source.

By Delivery Model:

• On-premises: Preferred by healthcare organizations for infrastructure control and data security, enabling compliance with strict regulations.
• Hosted: Not separately described in detail in source.

By Application:

• Training and Education: Facilitates access to digital slides and interactive learning environments.
• Consulting Services: Not separately described in detail in source.
• Intraoperative Consultation: Not separately described in detail in source.
• Routine Diagnostic Consultation Services: Core application involving standard evaluations to diagnose diseases, enhancing efficiency and data retrieval.
• Others: Not separately described in detail in source.

By End-User:

• Pharmaceutical & Biotechnology Companies: Not separately described in detail in source.
• Hospitals and Reference Laboratories: Not separately described in detail in source.
• Academic & Research Institutes: Leads with about 45.7% market share in 2024, supporting comprehensive educational and research programs.

Regional Insights

In 2024, North America held over 40.7% of the digital pathology market revenue share. The North American market is driven by the better healthcare infrastructure in the region, the early adoption of digital pathology systems, and increasing investment in healthcare IT infrastructure in the region. The leadership has rallied around these favorable regulations, including multiple approvals from the US FDA and a trend towards personalized medicine, requiring microscopic inspection.

Recent Developments & News

• March 2025: Royal Philips expanded partnership with Ibex Medical Analytics to enhance AI-enabled digital pathology workflows with Philips IntelliSite Pathology Solution (PIPS) 6.0, showing 37% productivity gains.
• January 2025: Roche obtained FDA 510(k) clearance for VENTANA DP 600 scanner with high throughput capacity to support cancer diagnosis.
• February 2025: Charles River Laboratories and Deciphex extended partnership to integrate Deciphex’s Patholytix platform into toxicologic pathology workflows.
• March 2025: Epredia received FDA clearance for E1000 Dx Digital Pathology Solution to enhance cancer diagnostic workflows with high-speed scanning.
• December 2024: Sheba Medical Center and Roche partnered to improve NSCLC diagnostics using AI-powered digital pathology.
• December 2024: Indica Labs joined AWS Partner Network, validating cloud architecture for clinical deployments.
• November 2024: UAB Pathology launched Digital Pathology Transformation Project.
• November 2024: Egypt Healthcare Authority, Roche Diagnostics, and Roche Pharmaceuticals signed an MOU to advance digital pathology in Egypt.
• February 2024: Corista secured Health Canada Class II Medical Device License for its DP3 platform.

Key Players

• DHISTECH
• Apollo Enterprise Imaging
• Corista
• Hamamatsu Photonics
• Huron Digital Pathology
• Indica Labs
• Koninklijke Philips
• Leica Biosystems
• Objective Pathology Services
• Ventana Medical Systems
• Visiopharm
• XIFIN

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask Our Expert & Browse Full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=1836&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302